Prime Medicine Q3 net loss $50.6M; cash $227M funds into 2027; AATD candidate nominated

Prime Medicine, Inc.

2025-Q3 EPS reported -$1.11 revenue$3,794,000

Net loss $50.6M vs $52.5M in Q3 2024; R&D spend $44.0M (+9% YoY) driven by license costs.
Cash and investments $227M; company expects runway into 2027 under current plans.
Nominated PM647 as AATD development candidate; IND/CTA on track for mid-2026 with clinical data in 2027.
Wilson's Disease program PM577 on track for IND/CTA in H1 2026; initial data expected in 2027.
Appointed Matthew Hawryluk, Ph.D., M.B.A. as Chief Business Officer to lead strategy and partnerships.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.